Latest Insider Transactions at Adaptive Biotechnologies Corp (ADPT)
This section provides a real-time view of insider transactions for Adaptive Biotechnologies Corp (ADPT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Adaptive Biotechnologies Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Adaptive Biotechnologies Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 23
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,790
-10.1%
|
$319,390
$41.93 P/Share
|
|
Mar 23
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,790
+9.17%
|
$46,740
$6.32 P/Share
|
|
Mar 19
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.14%
|
$210,000
$42.22 P/Share
|
|
Mar 18
2021
|
Jyoti Palaniappan SVP, Diagnostics, T-Detect |
SELL
Open market or private sale
|
Direct |
16,052
-28.15%
|
$706,288
$44.06 P/Share
|
|
Mar 18
2021
|
Jyoti Palaniappan SVP, Diagnostics, T-Detect |
BUY
Exercise of conversion of derivative security
|
Direct |
16,052
+38.9%
|
$353,144
$22.55 P/Share
|
|
Mar 18
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.09%
|
$210,000
$42.83 P/Share
|
|
Mar 17
2021
|
Katey Einterz Owen Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,443
+50.0%
|
-
|
|
Mar 17
2021
|
Leslie Trigg Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,443
+50.0%
|
-
|
|
Mar 17
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.09%
|
$220,000
$44.17 P/Share
|
|
Mar 16
2021
|
Michelle Renee Griffin Director |
SELL
Open market or private sale
|
Direct |
1,500
-49.93%
|
$70,500
$47.0 P/Share
|
|
Mar 16
2021
|
Michelle Renee Griffin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+33.3%
|
$10,500
$7.8 P/Share
|
|
Mar 15
2021
|
Francis Lo Chief People Officer |
SELL
Open market or private sale
|
Direct |
2,000
-4.52%
|
$82,000
$41.8 P/Share
|
|
Mar 15
2021
|
Francis Lo Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+8.13%
|
$14,000
$7.8 P/Share
|
|
Mar 15
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
1,354
-2.82%
|
$55,514
$41.54 P/Share
|
|
Mar 15
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Exercise of conversion of derivative security
|
Direct |
1,354
+5.29%
|
$41,974
$31.71 P/Share
|
|
Mar 15
2021
|
Michelle Renee Griffin Director |
SELL
Open market or private sale
|
Direct |
4,500
-42.71%
|
$184,500
$41.53 P/Share
|
|
Mar 15
2021
|
Michelle Renee Griffin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+42.84%
|
$31,500
$7.8 P/Share
|
|
Mar 10
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-31.64%
|
$420,000
$42.54 P/Share
|
|
Mar 10
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+24.04%
|
$60,000
$6.32 P/Share
|
|
Mar 10
2021
|
David E. Goel Director |
SELL
Open market or private sale
|
Indirect |
56,000
-0.23%
|
$2,296,000
$41.93 P/Share
|
|
Mar 09
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-17.48%
|
$400,000
$40.41 P/Share
|
|
Mar 09
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+24.35%
|
$60,000
$6.32 P/Share
|
|
Mar 09
2021
|
David E. Goel Director |
SELL
Open market or private sale
|
Indirect |
250,000
-0.99%
|
$10,000,000
$40.79 P/Share
|
|
Mar 08
2021
|
Robert Hershberg Director |
SELL
Open market or private sale
|
Direct |
4,000
-78.54%
|
$176,000
$44.56 P/Share
|
|
Mar 08
2021
|
Robert Hershberg Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+43.17%
|
$0
$0.45 P/Share
|
|
Mar 08
2021
|
David E. Goel Director |
SELL
Open market or private sale
|
Indirect |
500,000
-0.77%
|
$20,000,000
$40.05 P/Share
|
|
Mar 04
2021
|
Susan Bobulsky Chief Commercial Officer, MRD |
BUY
Grant, award, or other acquisition
|
Direct |
9,158
+50.0%
|
-
|
|
Mar 04
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,604
+48.82%
|
-
|
|
Mar 04
2021
|
Chad M Robins CEO and Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
68,681
+3.72%
|
-
|
|
Mar 04
2021
|
Francis Lo Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,604
+50.0%
|
-
|
|
Mar 04
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Grant, award, or other acquisition
|
Direct |
22,894
+50.0%
|
-
|
|
Mar 04
2021
|
R Mark Adams Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,604
+22.59%
|
-
|
|
Mar 04
2021
|
Jyoti Palaniappan SVP, Diagnostics, T-Detect |
BUY
Grant, award, or other acquisition
|
Direct |
9,158
+50.0%
|
-
|
|
Mar 04
2021
|
Stacy L Taylor SVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
13,736
+47.74%
|
-
|
|
Mar 04
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,681
+49.75%
|
-
|
|
Mar 04
2021
|
Julie Rubinstein President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
45,788
+50.0%
|
-
|
|
Mar 04
2021
|
Lance Baldo Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,894
+50.0%
|
-
|
|
Mar 01
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
6,771
-95.86%
|
$385,947
$57.87 P/Share
|
|
Mar 01
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Exercise of conversion of derivative security
|
Direct |
6,771
+34.03%
|
$40,626
$6.79 P/Share
|
|
Mar 01
2021
|
Michael J Pellini Director |
SELL
Open market or private sale
|
Direct |
20,000
-100.0%
|
$1,140,000
$57.8 P/Share
|
|
Mar 01
2021
|
Michael J Pellini Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$120,000
$6.55 P/Share
|
|
Mar 01
2021
|
Julie Rubinstein President and COO |
SELL
Open market or private sale
|
Direct |
15,000
-74.35%
|
$870,000
$58.39 P/Share
|
|
Mar 01
2021
|
Julie Rubinstein President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.55 P/Share
|
|
Feb 26
2021
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
2,812
-30.02%
|
$154,660
$55.44 P/Share
|
|
Feb 26
2021
|
Stacy L Taylor SVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,812
+30.44%
|
$19,684
$7.18 P/Share
|
|
Feb 26
2021
|
Julie Rubinstein President and COO |
SELL
Open market or private sale
|
Direct |
15,000
-100.0%
|
$840,000
$56.23 P/Share
|
|
Feb 26
2021
|
Julie Rubinstein President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.55 P/Share
|
|
Feb 25
2021
|
Julie Rubinstein President and COO |
SELL
Open market or private sale
|
Direct |
14,675
-97.96%
|
$821,800
$56.73 P/Share
|
|
Feb 25
2021
|
Julie Rubinstein President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,675
+50.0%
|
$88,050
$6.55 P/Share
|
|
Feb 24
2021
|
Julie Rubinstein President and COO |
SELL
Open market or private sale
|
Direct |
15,000
-54.37%
|
$855,000
$57.91 P/Share
|